Cancer Biopsy Market Report Scope & Overview:

The Cancer Biopsy Market Size was valued at USD 30.2 billion in 2023 and is expected to reach USD 56.3 billion by 2031, and grow at a CAGR of 8.1% over the forecast period 2024-2031.

The introduction of cancer biopsy and continuing advances in biopsy techniques are intended to have a significant impact on market growth. In addition, a number of biopsy techniques are used in the field of oncology diagnostics such as endoscopic, bone marrow, skin, needle and surgeon biopsies. The emergence of liquid biopsy in cancer diagnosis, screening, prognosis, and treatment monitoring has sparked significant competition and advancements within the market. Companies actively engaged in adopting or conducting liquid biopsies are considered pivotal catalysts for growth in clinical settings. For example, in June 2023, LabCorp launched a liquid biopsy designed to detect cancer-related biomarkers. This groundbreaking blood test holds the potential to enable cancer patients to initiate highly effective treatments at the earliest feasible stage.

Cancer-Biopsy-Market Revenue Analysis

Get more information on Cancer Biopsy  Market - Request Sample Report



  • Increasing awareness in order to drive growth of the market

  • The introduction of liquid biopsy is expected to bolster market growth

The introduction of fluid biopsy is expected to be one of the main drivers for growth on the global cancer biopsy market over the forecast period. For example, a liquid biopsy is used to analyse circulating DNACFDNA from cells that are excreted into the bloodstream by all types of tumors in patients with metastatic cancer. Labcorp launched a liquid biopsy for the detection of biomarkers associated with cancer on June 23, 2023. The new Labcorp blood test may help cancer patients get the best possible treatment as quickly as possible. The objective of this test is to analyze the genetic makeup of both advanced and metastatic solid tumors.


  • The possibilities of reimbursement that are not known

  • The growth of the market is being hampered by a large amount of diagnostic costs

The high cost of diagnosis is one of the main factors likely to hinder growth in the cancer biopsy market. Diagnostic tests of cancer are very expensive and increase the financial burden on families of patients. Therefore, these tests are not accessible to a middle-class patient population who does not have insurance. Furthermore, the cost of detecting cancer is not covered by several private insurers and this makes it difficult to use screening tools. However, with increasing medical tourism and diagnostic solutions becoming more affordable, this scenario is expected to change in the next few years.


  • Increasing the geriatric population

  • Rising burden of cancer across the globe

The growth opportunities for the cancer biopsy market are expected to be considerable in view of an increasing incidence of cancer worldwide. For instance, with the increasing prevalence of cancer, the use/adoption of cancer biopsy is also increasing with the rapid pace. As per projections from the American Cancer Society (ACS), the United States is anticipated to witness over 1,958,311 new cancer cases and 609,821 cancer-related deaths in 2023. Additionally, according to the Indian Council of Medical Research (ICMR), India may experience a 12.0% rise in cancer cases over the next five years, with approximately 1.5 million individuals expected to be afflicted by this non-communicable disease by 2025.


  • Market growth is hampered by technological and clinical challenges

The technical and medical challenges are another factor that hinders the growth of the global biopsy market for cancer. Several technical and clinical challenges related to the introduction of image guided biopsy in order to overcome costs and efficiency problems with surgery biopsies exist. For instance, some patients are predisposed to psychosocial, physical, or mental comorbidities that may restrict their participation & involvement in image-guided breast biopsy. The biopsy of the tissue is painful, invasive, costly and time consuming in spite of its informative nature; however, sometimes it's not necessary to remove tumour heterogeneity.

Impact of Russia-Ukraine War

Since Russia’s invasion of Ukraine, damage to key healthcare infrastructures, power outages, and shortages of medicine and food supplies have represented major hurdles for patients requiring time-critical interventions. In particular, oncology services have experienced significant disruption due to the fact that hospitals and health care providers must adjust their attention to trauma emergencies.  Furthermore, the conflict has begun to transfer a portion of Ukraine's cancer burden to neighboring nations. New solutions for managing the various aspects of cancer care in Ukraine are needed, given the unique problems associated with this disease. An important online meeting, the ECOASCO Special Meeting on the Impact of the War in Ukraine on Cancer, with over 200 participants, was held by the European Cancer Organization and the American Society of Clinical Oncologists. The ECO-ASCO Special Network on the Impact of War in Ukraine aims to bolster cooperation and coordination among oncology societies, cancer patient associations, and all entities striving to aid Ukrainian cancer patients. It aims to disseminate information in local languages, highlight and bolster ongoing efforts for Ukrainian patients, advocate to the World Health Organization (WHO), European Union (EU), and national governments, and adapt its strategies according to the evolving needs of the population while fostering partnerships with other relevant organizations.

Economic Slowdown

To enhance the health outcomes of the communities they serve, cancer centers must grasp the effects of external elements like unemployment, health insurance coverage, poverty, and accessibility of healthcare services. This understanding is crucial for identifying systemic factors that contribute to inferior cancer-related outcomes among the populations they cater to. However, conducting ecological studies to analyze population-level trends faces challenges due to shifts in health policies over time, variations in the enforcement of regulations, population movements into and out of specific areas, and localized differences at the community level. For instance, disparities in regulations related to tobacco have been linked to stable smoking rates in rural regions, whereas urban areas report a decline in smoking rates.

Market Segmentation

By Product

  • Instruments

  • Kits And Consumables

  • Services

Kits and consumables, as they are an integral part of the biopsy process across different stages with substantial investments made by key players in this sector, accounted for a revenue share of 61.71% from 2023. There is also a significant increase in the number of patients around the world who require instruments and kits that are efficient, accurate and rapid. Several developments in the area of instruments, kits and consumables have been observed with regard to cancer biopsy. For example, Summit Medical LLC announced in December 2022 the launch of a single use instrument to its Cervical Rotating Biopsy Punch product line that supports rapid diagnostic processes such as cancer diagnosis.


By Type

  • Tissue Biopsies

  • Needle Biopsies

  • Fine Needle Aspiration (FNA)

  • Core Needle Biopsy (CNB)

  • Surgical Biopsies

  • Liquid Biopsies

  • Others

The most lucrative revenue was generated by tissue biopsy and accounted for 62.3% of all revenues in 2023. It has been widely used for different cancer diagnosis applications, and continues to be seen as an essential component of biopsies. This is due to the strong research activities which have contributed to this segment's dominance of the global market over the forecast period, in assessing its safety and effectiveness. In the coming years, advances to improve tissue biopsy procedures should continue to maintain its dominant position on the worldwide market. On the other hand, Cernostics is working on an assay to diagnose Barrett's Esophagus in cancer patients. This diagnostic uses biopsy images which are digitally scanned to help analyse and quantify changes that occur at the level of cells or molecules in tissue.


Need any customization research on Cancer Biopsy Market - Enquire Now

By Application

  • Breast Cancer

  • Colorectal Cancer

  • Cervical Cancers

  • Lung Cancers

  • Prostate Cancers

  • Skin Cancers

  • Blood Cancers

  • Kidney Cancers

  • Liver Cancers

  • Pancreatic Cancers

  • Ovarian Cancers

  • Others

In 2023, breast cancer accounted for a market share of 15.5% and the same is expected to increase at an accelerated compound annual growth rate over the forecast period. Breast cancer has the highest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. For example, in 2022, in the US, women will be diagnosed with 287,851 new cases of invasive breast cancer, 51,401 cases of DCIS, and 43,251 will pass away from breast cancer.

Regional Analysis

The North America market, accounting for 40.7% of the total revenue generated in 2023, was the most profitable. The dominant share of North America in the forecast is expected to remain, with the US contributing significantly towards regional revenues. Furthermore, distributors and manufacturers in this region are seeking to distribute new kits that can be used rapidly for diagnostic purposes. In addition, the profitable strategies set out by the relevant government bodies are largely supportive of an increasing adoption of liquid biopsies throughout the United States. The framework, developed in recent years by the US Food and Drug Administration, relies on regulatory strategies for liquid biopsy-based oncology diagnostics.

Europe and Asia Pacific are also expected to experience strong growth in the biopsy market worldwide due to the growing prevalence of cancer, an ageing population, increased awareness among people and further adoption of liquid biopsies in these regions. For example, the European Liquid Biopsy Academy (ELBA) project, which is an Innovative Training Network (ITN), seeks to advance the promising technology of liquid biopsies from its initial stages and integrate it into clinical practice, particularly focusing on early diagnosis of Non-Small Cell Lung Cancer (NSCLC). Furthermore, as the cancer burden continues to grow, there is a corresponding increase in the adoption of cancer biopsies.



North America

  • US

  • Canada

  • Mexico


  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of the Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America


Some of the major players are as follows: ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players.

F. Hoffmann-La Roche Ltd-Company Financial Analysis

Company Landscape Analysis

Recent Developments:

  • In January 2023, Qiagen announced the acquisition of Verogen, a NGS Forensics Company that will contribute to strengthening its product portfolio and thus increase its global footprint.

  • In June 2023, QIAGEN reports that as part of the National Initiative in Denmark to provide sequencing solutions for patients with cancer, it is providing variant interpretation and reporting software called QIAGEN Clinical Insight QCI Interpret.

  • In January 2023, C2i Genomics, a leading company in the field of cancer intelligence, has joined forces with Onco DNA, which specializes in precision medicine for patients with cancer and hereditary disorders, to expand its activities into Europe's market. Their common goal is to advance the field of personalised medicine for patients who are affected by cancer or inherited diseases.

Cancer Biopsy Market Report Scope:
Report Attributes Details
Market Size in 2023 US$30.2 Billion
Market Size by 2031 US$ 56.3 Billion
CAGR CAGR of 8.1% From 2024 to 2031
Base Year 2023
Forecast Period 2024-2031
Historical Data 2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product (Instruments, Kits and Consumables, Services)
• By Type (Tissue Biopsies, Liquid Biopsies, Others)
• By Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Others)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players.
DRIVERS • Oncology Disorders are becoming more common, and liquid biopsies are becoming more popular.
• Technological Advancement
• Inherited Oncology Disorders and Genetic Testing are becoming more well-known.
OPPORTUNITIES • Biopsy Procedure-Related Risks
• Reimbursement possibilities that are unclear

Frequently Asked Questions

Kits and consumables, which are essential at various phases of biopsies, made for the greatest sales share

North America had the largest share of almost 40.0 percent. Throughout the projected period, the area is expected to maintain its lead, with the United States contributing significantly to regional revenue.

Cancer Biopsy Market is divided into three segments and they are By Product, By Type, and By Application

Biopsy Procedure-Related Risks, Reimbursement possibilities that are unclear are the restraints of the Cancer Biopsy market.

Cancer Biopsy market is expected grow at a CAGR of 7.6% over the forecast period 2024-2031.


1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Industry Flowchart

3. Research Methodology

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

5. Impact Analysis

5.1 Impact of Russia-Ukraine Crisis

5.2 Impact of Economic Slowdown on Major Countries

5.2.1 Introduction

5.2.2 United States

5.2.3 Canada

5.2.4 Germany

5.2.5 France

5.2.6 UK

5.2.7 China

5.2.8 Japan

5.2.9 South Korea

5.2.10 India

6. Value Chain Analysis

7. Porter’s 5 Forces Model

8.  Pest Analysis

9. Cancer Biopsy Market, By Product

9.1 Introduction

9.2 Trend Analysis

9.3 Instruments

9.4 Kits and Consumables

9.5 Services

10. Cancer Biopsy Market, By Type

10.1 Introduction

10.2 Trend Analysis

10.3 Tissue Biopsies

10.3.1 Needle Biopsies Fine Needle Aspiration (FNA) Core Needle Biopsy (CNB)

10.3.2 Surgical Biopsies

10.4 Liquid Biopsies

10.5 Others

11. Cancer Biopsy Market, By Application

11.1 Introduction

11.2 Trend Analysis

11.3 Breast Cancer

11.4 Colorectal Cancer

11.5 Cervical Cancers

11.6 Lung Cancers

11.7 Prostate Cancers

11.8 Skin Cancers

11.9 Blood Cancers

11.10 Kidney Cancers

11.11 Liver Cancers

11.12 Pancreatic Cancers

11.13 Ovarian Cancers

11.14 Others

12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Eastern Europe Poland Romania Hungary Turkey Rest of Eastern Europe

12.3.2 Western Europe Germany France UK Italy Spain Netherlands Switzerland Austria Rest of Western Europe

12.4 Asia-Pacific

12.4.1 China

12.4.2 India

12.4.3 Japan

12.4.4 South Korea

12.4.5 Vietnam

12.4.6 Singapore

12.4.7 Australia

12.4.8 Rest of Asia Pacific

12.5 The Middle East & Africa

12.5.1 Middle East UAE Egypt Saudi Arabia Qatar Rest of the Middle East

11.5.2 Africa Nigeria South Africa Rest of Africa

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Colombia

12.6.4 Rest of Latin America

13. Company Profiles

13.1 ANGLE Plc

13.1.1 Company Overview

13.1.2 Financial

13.1.3 Products/ Services Offered

13.1.4 SWOT Analysis

13.1.5 The SNS View

13.2 BD (Becton, Dickinson and Company)

13.2.1 Company Overview

13.2.2 Financial

13.2.3 Products/ Services Offered

13.2.4 SWOT Analysis

13.2.5 The SNS View

13.3 Biocept, Inc.

13.3.1 Company Overview

13.3.2 Financial

13.3.3 Products/ Services Offered

13.3.4 SWOT Analysis

13.3.5 The SNS View

13.4 Danaher

13.4.1 Company Overview

13.4.2 Financial

13.4.3 Products/ Services Offered

13.4.4 SWOT Analysis

13.4.5 The SNS View

13.5 F. Hoffmann-La Roche Ltd.

13.5.1 Company Overview

13.5.2 Financial

13.5.3 Products/ Services Offered

13.5.4 SWOT Analysis

13.5.5 The SNS View

13.6 Hologic, Inc.

13.6.1 Company Overview

13.6.2 Financial

13.6.3 Products/ Services Offered

13.6.4 SWOT Analysis

13.6.5 The SNS View

13.7 Illumina, Inc.

13.7.1 Company Overview

13.7.2 Financial

13.7.3 Products/ Services Offered

13.7.4 SWOT Analysis

13.7.5 The SNS View

13.8 Myriad Genetics

13.8.1 Company Overview

13.8.2 Financial

13.8.3 Products/ Services Offered

13.8.4 SWOT Analysis

13.8.5 The SNS View

13.9 Qiagen N.V.

13.9.1 Company Overview

13.9.2 Financial

13.9.3 Products/ Services Offered

13.9.4 SWOT Analysis

13.9.5 The SNS View

13.10 Thermo Fisher Scientific, Inc

13.10.1 Company Overview

13.10.2 Financial

13.10.3 Products/ Services Offered

13.10.4 SWOT Analysis

13.10.5 The SNS View

14. Competitive Landscape

14.1 Competitive Benchmarking

14.2 Market Share Analysis

14.3 Recent Developments

14.3.1 Industry News

14.3.2 Company News

14.3.3 Mergers & Acquisitions

15. Use Case and Best Practices

16. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone